Does insurance cover Mounjaro?

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, you’re probably asking the same question thousands of Americans face every day: Will my insurance actually cover this?

The short answer is complicated. While these breakthrough medications have transformed weight management and diabetes care, navigating insurance coverage feels like solving a puzzle—with pieces that change depending on your insurance type, state, diagnosis, and even your employer’s benefits package.

This guide breaks down exactly what you need to know about GLP-1 insurance coverage in 2025, including who qualifies, common denial reasons, state-by-state Medicaid differences, and what to do if your claim gets rejected.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into coverage, let’s clarify what we’re talking about:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like high blood pressure or type 2 diabetes.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes management. It’s the same active ingredient as Wegovy, but at different doses and with a different intended use. Many people use Ozempic off-label for weight loss, but this creates insurance complications.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. It works similarly to Ozempic but targets two hormone receptors instead of one. Mounjaro’s weight-loss version is called Zepbound.

The FDA indication matters enormously for insurance coverage. Your insurer will cover a medication for its approved use—but rarely for off-label purposes.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Does Commercial Insurance Cover GLP-1 Medications?

For Diabetes (Ozempic & Mounjaro)

Good news: Most commercial health plans cover Ozempic and Mounjaro when prescribed for type 2 diabetes. Since diabetes treatment is considered an essential health benefit under the Affordable Care Act, insurers generally include these medications on their formularies.

The catch: You’ll typically face prior authorization requirements. Your doctor will need to document your diabetes diagnosis, A1c levels, and often prove you’ve tried first-line treatments like metformin before approving a GLP-1 medication. Most plans place these drugs in Tier 3 (non-preferred brand) or Tier 4 (specialty), meaning higher copays—often $50-$200 per month with insurance, or 20-40% coinsurance.

What won’t be covered: Using Ozempic or Mounjaro off-label for weight loss. If you don’t have diabetes and your doctor prescribes Ozempic for weight management, commercial insurers will almost certainly deny coverage.

For Weight Loss (Wegovy)

The reality: Coverage for Wegovy is far less consistent. While some employer-sponsored plans include obesity medications, many specifically exclude them as ‘optional’ benefits to control costs. A 2024 KFF survey found that fewer than half of large employers cover GLP-1 drugs for weight loss, with many citing budget concerns over medications that can cost $1,000+ per month per patient.

If your plan does cover Wegovy, expect strict requirements:

• BMI threshold: Usually ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, high cholesterol, sleep apnea)
• Documented lifestyle attempts: Most insurers require proof of 6+ months of supervised diet and exercise programs
• Step therapy: Some plans mandate trying older, cheaper weight-loss medications first (like phentermine or Saxenda)
• Ongoing monitoring: Initial approvals often last just 3-6 months. Continued coverage requires demonstrating at least 5% weight loss
• Age restrictions: Typically limited to adults 18 and older (though pediatric use may be covered under different criteria)

According to Aetna’s clinical policy updated in May 2024, their prior authorization process requires all these elements plus regular provider documentation of treatment response.

Medicare Coverage: The Federal Exclusion

Here’s where it gets frustrating for older Americans: Medicare Part D does not cover medications used primarily for weight loss. This exclusion is written into federal law (Social Security Act Section 1927).

However, there’s an important exception: Medicare will cover Wegovy when prescribed for FDA-approved uses beyond weight loss. In March 2024, CMS announced that Medicare beneficiaries with obesity and established cardiovascular disease could receive Wegovy coverage for reducing heart attack and stroke risk—but only for that specific indication, not general weight management.

For diabetes management, Medicare Part D does cover Ozempic and Mounjaro because they’re treating a medical condition (type 2 diabetes), not just weight. Expect prior authorization, step therapy requirements, and placement in a higher cost-sharing tier.

Medicare Advantage plans have slightly more flexibility. Some MA plans began offering limited obesity medication coverage in 2025, but it’s not standard and varies widely by plan.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss medications varies dramatically by state because states have the option (not the obligation) to cover drugs for obesity.

As of late 2024, only about 13 states provided Medicaid coverage for medications like Wegovy—and that number is shrinking due to budget pressures.

States Currently Covering Wegovy (with major caveats):

New York: Covers Wegovy through its NYRx formulary with prior authorization requiring BMI ≥30 (or ≥27 with comorbidities), documented lifestyle modification, and quantity limits of 4 pens per 28 days.

Pennsylvania: Added coverage in 2023 with strict criteria—BMI thresholds, weight-related conditions, and mandatory diet/exercise documentation. But in a significant policy reversal, Pennsylvania will stop covering GLP-1s for weight loss in January 2026 due to cost concerns.

States NOT Covering Wegovy:

California: Perhaps most surprisingly, despite being a large progressive state, California’s Medi-Cal will eliminate coverage for Wegovy, Saxenda, and Zepbound on January 1, 2026. While these drugs were briefly covered in 2025 with prior authorization, budget impacts led to removal for all adults. Pediatric patients may still access coverage under EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions.

Texas: Never covered obesity medications for adults 21 and older. Texas Medicaid’s Vendor Drug Program explicitly excludes all weight-loss drugs including Wegovy, as announced in their March 2023 provider alert.

Florida: Does not cover anti-obesity medications under Medicaid, utilizing the federal exclusion option. Only diabetes-indicated GLP-1s are formulary drugs.

Illinois: No coverage for weight-loss GLP-1s under Medicaid, though the state expanded coverage for state employees in 2023.

This state-by-state variation creates significant health equity concerns. Medicaid beneficiaries—who often have higher obesity rates and related health conditions—have the least access to these breakthrough medications.

Common Reasons Insurance Denies GLP-1 Coverage

Understanding why claims get denied helps you prevent problems before they start:

1. Not Meeting Medical Necessity Criteria

The most common denial reason. Your documented BMI might be 29.5 when the plan requires 30, or you may lack a qualifying comorbidity when using the ≥27 BMI pathway. Even small documentation gaps trigger denials.

2. Insufficient Documentation of Prior Attempts

Plans want proof you’ve tried lifestyle modifications first. Simply stating ‘patient attempted diet and exercise’ in your chart isn’t enough. Insurers look for documented participation in supervised programs, weight logs, nutritional counseling records, or commercial weight-loss program enrollment spanning at least 6 months.

3. Step Therapy Requirements Not Met

For obesity treatment, some insurers require trying older medications (phentermine, orlistat, Contrave) first. For diabetes, you may need documented trials of metformin, sulfonylureas, or other GLP-1s before Mounjaro approval. Skipping these steps results in automatic denials.

4. Off-Label Use

Prescribing Ozempic to a non-diabetic patient for weight loss will be denied, even if clinically appropriate. Insurers strictly enforce FDA-approved indications.

5. Plan Exclusions

Some employer plans specifically exclude ‘drugs for weight reduction or control’ in their policy documents. No amount of documentation overcomes a contractual exclusion. Check your Summary of Benefits or call member services to ask if obesity medications are a covered benefit.

6. Formulary Restrictions

Even if your plan covers GLP-1s in theory, they might not cover your specific drug. Some plans prefer Saxenda over Wegovy, or require trying one GLP-1 before another. Formulary tier placement also affects coverage—drugs on higher tiers face more restrictions.

How to Navigate the Prior Authorization Process

Getting approval requires strategy and persistence:

Before Submitting:

1. Verify coverage: Call your insurance and ask specifically: ‘Does my plan cover [drug name] for [your diagnosis]?’ Get the representative’s name and reference number.

2. Review criteria: Request a copy of the prior authorization criteria from your insurer. This tells you exactly what documentation you’ll need.

3. Gather documentation: Work with your healthcare provider to compile:

• Measured height and weight with calculated BMI
• Lab results showing A1c (if diabetic) or evidence of comorbidities
• Records from weight-loss programs, nutritionist visits, or documented diet attempts
• Previous medication trials and why they failed or were insufficient
• Any relevant imaging or specialist reports

1. Write a compelling letter of medical necessity: Your provider should detail why this specific medication is appropriate for you, referencing clinical guidelines and your individual circumstances.

During the Process:

• Follow up regularly: Insurance companies have 72 hours for urgent requests and 5-14 business days for standard requests, but delays happen. Call weekly for status updates.

• Document everything: Keep notes of every phone call, including date, time, representative name, and what was said.

• Meet deadlines: If the insurer requests additional information, respond immediately. Delays restart the clock.

If Denied:

Don’t accept the first denial. Appeal success rates vary, but many initial denials are overturned when you provide missing documentation or clarify misunderstandings.

Request a formal appeal within the timeframe specified (usually 180 days). Your denial letter will include instructions.

Escalate if needed: If internal appeals fail, you may request external review by an independent third party. For commercial insurance, your state’s Department of Insurance can sometimes intervene.

Consider alternatives: While appealing, ask your provider about:

• Trying the appeal with a different medication that might have less restrictive coverage
• Accessing patient assistance programs (discussed below)
• Using GoodRx or manufacturer discount programs for self-pay

At Klarity Health, our providers understand these insurance complexities and can help document your case thoroughly, increasing your chances of approval. We work with both insured and cash-pay patients to find the most affordable pathway to treatment.

Self-Pay Options When Insurance Won’t Cover GLP-1s

If insurance denies coverage or you don’t have insurance, don’t give up. Recent pricing changes have made these medications more accessible:

Manufacturer Discount Programs

Novo Nordisk (makes Wegovy and Ozempic):

• For insured patients with coverage: Savings card reduces copays to as low as $0-$25 per month (saves up to $225 monthly)
• For cash-pay patients: The Wegovy Access program through NovoCare now offers $349/month (down from previous $499), or use the GoodRx partnership for $199/month for the first two months, then $349/month
• Patient assistance program: Free medication for uninsured patients who meet income requirements

Eli Lilly (makes Mounjaro and Zepbound):

• Savings card for diabetes: Reduces Mounjaro to $25/month for commercially insured patients with type 2 diabetes
• Self-pay program for weight loss: Zepbound single-dose vials now $299-$449/month (depending on dose) through LillyDirect
• Patient assistance: Free medication available based on income

GoodRx Special Pricing

In November 2025, GoodRx partnered with Novo Nordisk to offer unprecedented discounts:

• Wegovy or Ozempic: $199/month for the first two fills
• Ongoing price: ~$349/month for most doses
• Available at nearly all pharmacies nationwide with a GoodRx coupon
• No insurance needed; purely cash-pay pricing

This represents a 60-70% discount from list prices of $1,000+.

Cost Comparison Table

Avoiding Compounded Medications

Some telehealth companies offer compounded semaglutide or tirzepatide at lower prices (sometimes $200-$300/month). Exercise caution here. These are not FDA-approved products. While compounding pharmacies serve legitimate needs, the quality, purity, and dosing of compounded GLP-1s vary widely and carry risks. The FDA has issued warnings about compounded semaglutide due to dosing errors and contamination concerns.

Stick with FDA-approved, brand-name medications from legitimate pharmacies whenever possible.

Does Insurance Cover Telehealth Visits for Weight Loss?

Yes—and telehealth may actually improve your access to care.

Since the COVID-19 pandemic, insurance coverage of telehealth has expanded dramatically. Over 40 states now have telehealth parity laws requiring private insurers to cover virtual visits the same as in-person appointments.

For weight management specifically:

• Preventive obesity counseling is an ACA-mandated benefit, meaning most plans must cover it at no cost
• Chronic disease management (including diabetes and obesity-related conditions) is widely covered via telehealth
• Nutritional counseling for obesity is typically covered, whether virtual or in-person

What to verify:

• Your provider must be in-network (or your plan must allow out-of-network telehealth)
• Some insurers require live video (not just phone calls or messaging)
• Check if your plan requires a referral or pre-authorization for specialist visits

Klarity Health offers both insured and cash-pay telehealth visits for weight management and GLP-1 prescriptions. Our transparent pricing means you’ll know your costs upfront, and we accept many major insurance plans. With providers available across multiple states, you can often get an appointment within days—not weeks—making it easier to start treatment or handle urgent prescription needs.

Even if your insurance doesn’t cover the medication itself, virtual consultations for weight management are typically covered, reducing your overall out-of-pocket costs.

Medication Coverage Summary: Quick Reference

What This Means for You: Practical Next Steps

If you’re considering GLP-1 medications, here’s your action plan:

1. Determine your diagnosis and treatment goal

• For type 2 diabetes: You’ll likely get coverage for Ozempic or Mounjaro with proper documentation
• For weight loss: Coverage is much harder but not impossible, especially with obesity-related health conditions

2. Check your specific coverage

• Call your insurance and ask about formulary placement and prior authorization requirements
• If you have Medicaid, verify your state’s obesity medication policy
• Request a copy of PA criteria so you know exactly what’s needed

3. Work with a knowledgeable provider

• Choose a provider experienced in GLP-1 medications and insurance authorization
• Ensure thorough documentation of your weight history, comorbidities, and prior attempts
• Telehealth providers like Klarity Health specialize in these treatments and understand the approval process

4. Prepare for potential denial and appeal

• Have a backup plan (patient assistance, cash-pay options)
• Don’t be discouraged by initial denials—many are overturned
• Use manufacturer savings programs to bridge gaps in coverage

5. Explore all cost-saving options

• Apply for manufacturer savings cards even if you have insurance
• Compare GoodRx prices to your insurance copay—sometimes cash-pay is cheaper
• Investigate patient assistance programs if you meet income requirements

The Bottom Line on GLP-1 Insurance Coverage

Insurance coverage for Wegovy, Ozempic, and Mounjaro in 2025 remains complex and inconsistent. While diabetes use is generally covered with prior authorization, weight-loss coverage depends heavily on your specific insurance plan, state Medicaid policy, and employer benefits.

The good news: Recent manufacturer price reductions and innovative programs like GoodRx’s partnership pricing have made self-pay options far more accessible, with costs dropping to $199-$349/month for many patients.

Whether you’re navigating insurance approvals or considering cash-pay options, having an experienced provider in your corner makes all the difference. At Klarity Health, we offer:

• Transparent, upfront pricing for both insured and cash-pay patients
• Provider availability across multiple states for convenient telehealth appointments
• Expertise in GLP-1 medications and the prior authorization process
• Acceptance of major insurance plans while also offering affordable self-pay rates

Don’t let insurance confusion stand between you and effective treatment. With the right information, documentation, and support, accessing these life-changing medications is possible—whether through insurance coverage or affordable self-pay options.

Ready to explore your options? [Contact Klarity Health] to schedule a consultation and discuss the best pathway forward for your individual situation.

Frequently Asked Questions

Will my insurance cover Wegovy if I have a BMI of 28 and high blood pressure?

Possibly. Most insurers require BMI ≥30, or ≥27 with at least one weight-related comorbidity. High blood pressure (hypertension) typically qualifies as a comorbidity. You’ll need prior authorization with documentation of your BMI, blood pressure diagnosis, and usually 6+ months of supervised diet/exercise attempts. Coverage isn’t guaranteed—it depends on your specific plan’s obesity drug policy.

Can I get Ozempic covered for weight loss if I don’t have diabetes?

Not through insurance. Insurers only cover Ozempic for its FDA-approved use: type 2 diabetes. Prescribing it off-label for weight loss in non-diabetic patients will result in denial. If you want insurance coverage for weight loss, you’d need a prescription for Wegovy (the weight-loss formulation) and meet your plan’s criteria. Alternatively, you could pay cash for Ozempic using manufacturer programs or GoodRx discounts ($199-$349/month).

How long does the prior authorization process take?

Typical turnaround is 5-14 business days for standard requests, though insurers must respond to urgent requests within 72 hours. However, if your insurer requests additional documentation, the timeline extends. Proactive submission of complete documentation upfront speeds approval. Stay in contact with both your provider’s office and insurance to track progress.

What happens if my insurance approves Wegovy but I don’t lose enough weight?

Most insurance approvals for weight-loss medications are time-limited (often 3-6 months initially). To continue coverage, you’ll need to demonstrate adequate progress—typically at least 5% weight loss from baseline. If you don’t meet these targets, your insurer may deny continued coverage. Work closely with your provider to optimize your treatment plan and document any extenuating circumstances that might warrant continued therapy.

Does Medicaid in my state cover GLP-1s for weight loss?

It depends on your state. As of late 2025, only about 13 states cover obesity medications under Medicaid, and several are eliminating coverage due to costs (California and Pennsylvania end coverage January 1, 2026). Check with your state Medicaid program or ask your provider. Even in states with coverage, expect strict prior authorization requirements. Children and adolescents may have better access through EPSDT provisions.

Are generic versions of these medications available?

No. Wegovy, Ozempic, and Mounjaro are all brand-name medications with no FDA-approved generic equivalents as of 2025. Patents extend well into the 2030s, so generics won’t be available for years. Some compounding pharmacies make semaglutide or tirzepatide formulations, but these are not FDA-approved and carry quality and safety concerns. Stick with brand-name medications from legitimate pharmacies.

📅 Research Currency Statement (Verified as of December 17, 2025)

All coverage policies, pricing information, and formulary details in this article were verified against current sources as of December 17, 2025. Insurance coverage can change with new plan years or policy updates. Always confirm your specific plan’s coverage by contacting your insurance directly or reviewing your Summary of Benefits.

References

1. Aetna Clinical Policy Bulletin – Weight Loss (BMI ≥35) GIP-GLP-1, GLP-1 Agonists. May 2024. Available at: www.aetna.com

2. California Medical Association. ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal.’ December 2025. Available at: www.cmadocs.org

3. Cohen J. ‘Coverage of weight loss drugs by Medicaid plans continues to lag.’ Forbes. August 7, 2025. Available at: www.forbes.com

4. Kaiser Family Foundation. ‘Medicaid Coverage of and Spending on GLP-1s.’ Issue Brief. November 4, 2024. Available at: www.kff.org

5. Reuters. ‘Wegovy to be covered by U.S. Medicare for heart disease patients.’ March 21, 2024. Available at: www.reuters.com

6. Texas Children’s Health Plan. ‘Provider Alert: Non-formulary requests for obesity control drugs.’ April 28, 2023. Available at: www.texaschildrenshealthplan.org

7. Pennsylvania Health Law Project. ‘Pennsylvania Medicaid Covers Newer Weight Loss Drugs.’ 2024. Available at: www.phlp.org

8. WESA Pittsburgh. ‘Pa. Medicaid will stop covering some weight-loss drugs next month.’ December 4, 2025. Available at: www.wesa.fm

9. GoodRx (via BusinessWire). ‘GoodRx Launches New $39-Per-Month Weight Loss Telemedicine Subscription; Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®.’ November 17, 2025. Available at: www.businesswire.com

10. Fierce Pharma. ‘Novo unveils newly reduced self-pay prices for Wegovy, Ozempic after White House deal.’ November 2025. Available at: www.fiercepharma.com

11. Fierce Pharma. ‘Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs for single-dose Zepbound vials.’ December 2025. Available at: www.fiercepharma.com

12. SingleCare. ‘Cigna prior authorization for weight loss.’ October 2024. Available at: www.singlecare.com

13. iCanNotes. ‘Telehealth Parity Laws in 2025.’ August 6, 2025. Available at: www.icanotes.com

14. GoodRx Consumer Information. ‘How much is Mounjaro without insurance?’ April 2, 2025. Available at: www.goodrx.com

15. Solution Shortcut. ‘Medicaid Drug Coverage by State: 2025-2026 Updates.’ 2025. Available at: solutionshortcut.com

Insurance coverage policies, state Medicaid formularies, and manufacturer pricing programs are subject to change. This information is current as of December 17, 2025. Always verify coverage details with your specific insurance plan and consult healthcare providers for medical advice.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499